Wall Street expects a year-over-year increase in earnings on higher revenues when Glaukos (GKOS) reports results for the quarter ended March 2025. While this widely-known consensus outlook is ...

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, ...

Glaukos Corp., the most valuable public company in Orange County’s thriving ophthalmology sector, appears to be expanding its ...

Analysts have set 12-month price targets for Glaukos, revealing an average target of $170.86, a high estimate of $200.00, and ...

ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” first quarter ...

Mizuho lowered the firm’s price target on Glaukos (GKOS) to $175 from $200 and keeps an Outperform rating on the shares as part of a Q1 preview ...

Stifel lowered the firm’s price target on Glaukos (GKOS) to $140 from $175 and keeps a Buy rating on the shares. The firm surveyed 34 iDose ...

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases ...

Glaukos Co. (NYSE:GKOS – Get Free Report)’s stock price traded down 6.6% during mid-day trading on Wednesday after Mizuho lowered their price target on the stock from $200.00 to $175.00.

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to ...

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in ...

In the preceding three months, 7 analysts have released ratings for Glaukos (NYSE:GKOS), presenting a wide array of perspectives from bullish to bearish. In the table below, you'll find a summary ...